Gene Therapy Statistics:

Both ‘Competing’ Gene Therapy techniques, delivered using an AAV2-hAADC virus vector to either the Putamen or Substantia Nigra & VTA offer improvements to the severe condition Aromatic Amino Acid Decarboxylase deficiency. 


Our job at the AADC Trust is to provide support and facts to affected families which are in our possession regarding this invasive but pioneering brain surgery. 


With this families are able to make the most informed decision as to whether they take advantage of this treatment which is offering a dramatic improvement to severe AADCd symptoms for many.


Gene Therapy Stats:



  • More than 20 AADCd children have been treated with Gene Therapy (Putamen) in Taiwan.



  • More than 6 AADCd children have been treated with Gene Therapy (Putamen) in Japan.



  • 10 more AADCd children in Taiwan are expected to be treated on a Phase I/II trial during the next 18 months.



  • This trial is ACTIVE but NOT RECRUITING.



  • 8 AADCd children have been treated with Gene Therapy (Substantia Nigra Pars Compacta & Ventral Tegmental Area) in the USA.



  • 15 AADCd children have been treated with Gene Therapy (Substantia Nigra Pars Compacta & Ventral Tegmental Area) in Poland.



  • Considerably more children in Poland are expected to be treated over the next 18 months on a ‘not-for-profit’ basis.



  • 12 more AADCd children will be treated in the USA over the next 18 months, on the ‘Extended Single-Stage Trial’.



  • This trial is ACTIVE and RECRUITING.

If you are interested in registering for this trial please click on the link to find out more information. The email contact details are at the bottom of the link page..


A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients (AADC)



Krystof Bankiewicz



National Institutes of Health (NIH)



Information provided by (Responsible Party):

Krystof Bankiewicz, University of California, San Francisco


About The AADC Trust...



The AADC Research Trust has advocated on behalf of its sufferers for more than a decade and remains an important 'Worldwide' driving force, inspiring and funding most related research projects, including Gene Therapy.


It remains the only 'dedicated disease support group' available to a global community of sufferers and families. We pride ourselves on providing unbiased information, keeping them up to date and so allowing them to make the most informed decision about their children's futures.


quick links

stay in touch

find us

  • Grey LinkedIn Icon
  • Grey Facebook Icon
  • Grey Twitter Icon
  • Grey YouTube Icon
  • Grey Instagram Icon


To contact us please email via: and we will endeavour to reply to you as soon as possible. We apologise in advance for any delays in our response, during this time. Our staff are on furlough and working from home. Please bear with us. Thank you for your patience.


The AADC Research Trust

Soper Hall, 2 Harestone Valley Road,

Caterham, Surrey, CR3 6HY

Registered Charity

UK & Wales No: 1114367

© AADC Research Trust